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Patient-reported outcomes of ocriplasmin for the 
treatment of vitreomacular traction: a systematic 
review and synthesis of the literature
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3Life Sciences and Medicine, King’s 
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Hospital, London, UK
Purpose: Vitreomacular traction (VMT) is a disease in which the vitreous exerts abnormally 
strong traction on the macula, the area of the eye responsible for detailed central vision. If this 
traction significantly distorts the macula then VMT can lead to troublesome distorted vision 
(metamorphopsia), sometimes occurring despite relatively preserved visual acuity. Ocriplasmin, 
administered as a single intravitreal injection, aims to release VMT and improve vision. While 
the effect of ocriplasmin on traction release and visual acuity is well characterized, the effect 
of symptoms like metamorphopsia is not.
Methods: A systematic review and synthesis of the literature on patient reported outcomes 
(PRO) in relation to the use of ocriplasmin for the treatment of VMT was undertaken using MED-
LINE and Embase databases, and the Cochrane central register of controlled trials (CENTRAL).
Results: The review identified PRO data from 870 patients across three randomized controlled 
trials. The most commonly reported PROs were the 25-item National Eye Institute Visual 
Function Questionnaire (VFQ-25), a broad measure of vision-related quality of life, and Visual 
Function Response (VFR), an outcome combining quality of life and visual acuity outcomes. 
Treatment with ocriplasmin produced significant patient benefit vs control (sham or placebo-
injection). Ocriplasmin was associated with a higher proportion of patients experiencing a 
clinically meaningful improvement in visual functioning with a difference of 11.8% for VFQ-25 
and 23.2% for VFR responder analyses, respectively.
Conclusion: Patients with VMT have material impairment in visual functioning and quality of 
life, relative to their reduction in visual acuity. Ocriplasmin results in a significant improvement in 
visual functioning. Future research could include the development of new PROs specific to VMT.
Keywords: macular hole, metamorphopsia, patient reported outcomes, symptomatic vitreo-
macular adhesion, vitreomacular traction, visual function questionnaire
Plain language summary
Why was this study done? Most trials of new eye treatments rely on visual acuity eye charts 
to measure treatment success, but for some conditions eye charts fail to fully capture patients’ 
symptoms. This is particularly true for vitreomacular traction (VMT), a condition in which the 
watery gel inside the eye pulls on, and thereby damages, the light-receiving cells inside the 
back of the eye. Anatomic outcomes are therefore often used instead, but these are only a proxy 
for visual function. Patient reported outcomes (PRO) comprise patient questionnaires that may 
better capture the effects of VMT, and help quantify the effect of novel treatments. 
What did the researchers do and find? We systematically surveyed and brought together the 
medical literature on a new treatment for VMT, ocriplasmin. Ocriplasmin is a drug that is injected 
into the eye. It aims to dissolve the vitreous and resolve VMT. We aimed to summarize the PROs 
following ocriplasmin treatment, in comparison to placebo/simulated treatment. We limited our 
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analysis to high quality clinical trials. We found that ocriplasmin 
resulted in better PRO than placebo/simulated treatment. 
What do these results mean? PROs may offer insight into clini-
cal benefits that are better aligned to patient experience than visual 
acuity or anatomic success.
Introduction
Vitreomacular traction (VMT), also called symptomatic 
vitreomacular adhesion, is a disorder of the vitreoretinal inter-
face in which abnormal vitreous traction pulls on the macula, 
the light-sensitive layer of the eye that is responsible for fine 
central vision such as reading and driving. VMT occurs in 
the context of an incomplete posterior vitreous detachment, 
where persisting macular adhesion leads to distortion of the 
macular architecture.1,2 There is a wide spectrum of severity 
and clinical findings. Some patients have minimal symptoms, 
while others are bothered by decreased or distorted central 
vision and alteration in image size.3–5 Progressive traction 
can lead to the development of a hole in the macula and 
worsening visual function.6–8
In clinical practice and clinical trials, the most commonly 
used measure of visual function is visual acuity (VA), estab-
lished using eye charts. VA is effective at quantifying clear vs 
blurred vision, however it does not capture the entirety of visual 
disturbances in VMT.9,10 For example, most patients in large 
clinical trials of VMT presented with relatively good VA.11,12 
By contrast, metamorphopsia or distorted vision was found to 
be highly prevalent in patients with VMT, but is typically not 
measured in clinical practice because of lack of widely accepted 
clinical tools to identify and quantify the degree of distortion.13
There are three commonly used management options for 
VMT – observation, vitreolysis and vitrectomy. There are 
also small clinical case series investigating the use of a gas 
bubble to treat VMT.14 The current standard of care in early 
stage VMT is observation, a strategy that is often justified 
for people with no or few symptoms and in the expectation 
that some cases may resolve spontaneously. However, more 
severe VMT, and most macular holes, justify the potential 
risks of surgical intervention, namely pars plana vitrectomy.15 
Vitrectomy removes the vitreous and thereby the vitreomacu-
lar traction. Ocriplasmin is the only licensed pharmacologi-
cal treatment for VMT.11 Ocriplasmin is an enzyme that is 
injected directly into the vitreous, wherein it is designed to 
dissolve vitreous and release vitreomacular adhesion.16
Given the shortcomings of VA as an outcome measure, 
anatomic success (release of VMT and macular hole closure) 
is often used instead. Indeed, vitreomacular adhesion release 
at day 28 was the primary outcome measure in the  registration 
studies.11 This occurs in the expectation that visual symptoms 
will improve as the anatomical integrity of the vitreoretinal 
interface is restored.17,18 Nonetheless, anatomic success 
remains a proxy of visual function.
When clinical outcome measures fail to capture the impact 
of ophthalmic disease on a patient’s life, patient reported 
outcomes (PROs) may address the deficit in the clinician’s 
knowledge.5 A PRO describes any report or measure of the 
patient’s health that comes directly from the patient without 
interpretation by a clinician or a researcher.19 PRO instru-
ments were initially intended to supplement the physiological 
measures to better understand treatment effectiveness.20 In 
ophthalmology a vast number of PRO instruments have been 
developed to assess the patient’s perspective of the disease 
impact and treatment outcomes, however only a few retina-
specific disease instruments exist.20 The objective of this paper 
is to summarize, and where possible synthesize, the PROs 
relating to the use of ocriplasmin for the treatment of VMT.
Materials and methods
Study design and criteria for considering 
studies
We undertook a systematic literature review to identify 
relevant clinical data. We included studies meeting the fol-
lowing PICOS criteria:
Participants: patients with a diagnosis of symptomatic 
vitreomacular adhesion (VMA), including VMT and macular 
holes.
Intervention: treatment with an intravitreal injection of 
ocriplasmin.
Comparator: the intended control was natural history, 
intravitreal placebo, sham or gas injection.
Outcomes: patient-reported outcomes.
Study design: to maximize PRO data, randomized con-
trolled trials (RCTs), prospective, retrospective, controlled 
and uncontrolled studies were eligible.
The study protocol was registered with the interna-
tional prospective register of systematic reviews (2018: 
CRD42018109567, National Institute of Health Research 
Center for Reviews and Dissemination, University of York, 
UK) and conducted in accordance with Preferred Reporting 
Items for Systematic reviews and Meta-analyses (PRISMA) 
guidance (http:// www.prisma-statement.org/, accessed May 
27, 2018).
Inclusion criteria were as follows: studies of VMT or 
small to medium full thickness macular hole (FTMH) (≤400 
µm in diameter);1 any PRO outcome reported.
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Exclusion criteria included articles appearing as abstract 
only, animal studies, case reports, studies with fewer than 12 
subjects per arm, safety or clinical only reviews, editorials, 
commentary, and expert opinions.
Search strategy and information sources
We searched PubMed MEDLINE, Elsevier Embase data-
bases and the Cochrane central register of controlled tri-
als (CENTRAL) from inception date to October 3, 2018. 
In the absence of a validated methodological filter for 
identifying PRO and patient perspective studies a qual-
ity of life (QoL) search filter developed by Paisley et al 
was applied to identify PRO articles of interest.21,22 This 
QoL filter was further expanded by adding search terms 
for disease specific QoL instruments. The search strategy 
included the following search terms or keywords: quality of 
life; health-related QoL; quality adjusted life year; health 
state; health status; healthy years equivalents; life quality; 
utilities; wellbeing; short form 36 (SF-36); short form 12 
(SF-12); Euroqol; eq 5d; quality of wellbeing scale; health 
utilities index (HUI or HUI-3); medical outcomes survey; 
visual function questionnaire; VFQ; NEI VFQ; CatQuest; 
MacDQoL; time trade-off; standard gamble; willingness to 
pay; patient preferences; patient perspectives; utility index; 
vision bolt-on item; patient reported outcome; functional 
outcomes; patient outcomes; visual function; visual func-
tion 14 score. Full details on the PRO search strategy are 
presented in Table S1. These PRO terms were combined 
using Boolean operators with the search term for the 
intervention (microplasmin, ocriplasmin or JETREA) and 
disease (vitreomacular adhesion or traction).
Study selection
One reviewer (BL) assessed the records identified by the 
searches and classified each record as either 1) possibly 
relevant or 2) definitely not relevant. Full-text copies of all 
possibly relevant records were obtained, and one reviewer 
(BL) classified them as either 1) definitely include, 2) unsure 
or 3) definitely exclude based on the criteria for inclusion. 
 Discrepancies in eligibility were resolved by consensus 
following discussion (BL, TJ). Excluded records were 
documented.
Data extraction strategy
Relevant data from selected articles were extracted and sum-
marized by a first reviewer (BL) and a second reviewer (TJ) 
verified the abstracted data against full text. For all eligible 
articles, the following data were abstracted: author; year of 
publication; title; source; study objective(s); location(s). The 
data items on study characteristics included: participants: 
country, total number of participants, age, sex, inclusion and 
exclusion criteria; Intervention and comparator details; PRO 
measure: type and definition, PRO outcomes as measured 
and reported in the study; study design; length of follow-up; 
and years in which the study was conducted. All reviewers 
evaluated the articles and confirmed the inclusion of selected 
articles for this review. The information included for each 
article was reviewed by the reviewers to ensure congruence 
of information extracted. Any discrepancy was resolved by 
consensus between reviewers and documented in the review.
Assessment of risk of bias in included 
studies and heterogeneity among studies
Included studies were assessed for bias using the methods and 
grades described in the Cochrane Handbook for Systematic 
Reviews of Interventions. If applicable, heterogeneity among 
studies was assessed using an I2 value (>50%) to assess if vari-
ability in effect was due to sampling error. Diversity among 
studies was assessed by reviewing participant characteristics 
and trial methodology.
Data synthesis and analysis
Currently, there is no PRO measure that has been validated 
(testing of psychometric properties) specifically for use in 
a VMT population to assess the overall impact of the eye 
disorder on self-reported functional vision.23
The use of composite PRO measures has been favored as 
the morbidity associated with VMT is multifaceted. These 
composite endpoints traditionally included the VFQ-25 
which measures dimensions of patient-reported vision-
targeted health status that are thought to be most important 
to people with eye disease. Improvement in the VFQ-25 is 
evaluated using 12 subscale scores and a global composite 
score with higher scores indicating better health status.24,25 
More recently, another composite PRO was developed using 
principal component analysis (PCA), to comprehensively 
evaluate changes in vision-related functioning as experi-
enced by patients.26 A PCA reduces a multidimensional 
response into a restricted set of responses, called principal 
components, in an objective way while preserving as much 
of the overall variability in the multidimensional response 
as possible.27 A visual function response (composed of the 
first three dimensions of visual functioning according to 
PCA) was defined such that participants could be classified 
as responders or non-responders. Because PRO data may be 
assessed or analyzed using different analytical approaches, 
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authors and/or sponsors were contacted to obtain unpublished 
data where necessary.
iterative changes to the study protocol
As the systematic literature review identified PRO data 
from the ocriplasmin randomized clinical studies only, a 
quantitative pooled analysis of PRO results restricted to 
RCTs was added post hoc, with the measure of treatment 
effect being the proportion of responders for the PRO 
outcome. Risk difference and 95%CI between groups 
were based on the percentage of responses. To increase the 
statistical power of the analysis compared to the individual 
studies, PRO data were pooled across all studies using 
study means. For combined studies, we pooled risk dif-
ferences based on random effects model using the method 
of DerSimonian and Laird.28 If data availability allowed, 
we planned to perform subgroup analyses for the PRO 
outcome between participants who did, or not, achieve 
traction release at day 28.
Results
Description of studies
Results of the search
In total 88 records were identified (Figure 1) of which 86 
emerged from the three database searches. The electronic 
search was complemented by manually searching the refer-
ence lists of relevant articles in the databases and contact-
ing the manufacturer for unpublished data related to PRO 
measures. This resulted in one additional publication and 
one conference presentation.
After excluding 20 duplicate records, 68 records were 
screened based on title and abstract. From these, 31 references 
failed to meet the eligibility criteria: detailed anatomical, 
visual acuity, safety outcomes (8) or clinical reviews (3) 
rather than PRO; expert opinion (6); case reports (5); predic-
tive studies (2); other intervention (2); measurement tech-
nique to characterize macular structure and visual function 
(1); association anatomical and VA outcomes (1); study cost 
analysis (1); clinical trial number (1); abstract unavailable 
Figure 1 Study flow diagram
Abbreviations: vMA, vitreomacular adhesion; MH, macular hole.
Records identified through
database searching
(N=86)
Records after duplicates removed
(N=68)
Records screened
(N=68)
Full-text articles assessed
for eligibility
(N=37)
Studies included in
qualitative synthesis
(N=6)
Reason for exclusion full-text articles (N=31)
Clinical and/or safety review (4)
Modeling studies (4)
Abstract of subsequently published research (4)
Clinical and/or safety outcomes only (4)
Non-peer reviewed conference paper/abstract (3)
Microperimetry as biomarker of visual function (2)
Real world data clinical and/or safety outcomes (2)
Natural history (2)
Literature review (1)
Analysis relationship VMA resolution and MH
closure (1)
Meta-analysis of primary papers (1)
Study design description only (1)
Letter to editor (1)
Full text article in Chinese (1)
Records excluded
(N=31)
Additional records identified
through other sources
(N=2)
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(1). For the remaining 37 possibly relevant records, full-text 
publications were investigated, of which 31 articles were 
eliminated from the review for the following reasons: clini-
cal and/or safety review (4); modeling study (4); abstracts of 
original research already included in the review (4); clinical 
and/or safety outcomes (4); non-peer reviewed conference 
paper or abstract only (3); microperimetry studies (2); real 
world data on clinical and/or safety outcomes (2); natural 
history on spontaneous resolution or visual acuity outcomes 
(2); analysis on interrelations between anatomical outcomes 
and/or visual acuity (1); literature review of symptomatic 
VMA (1); meta-analysis of primary papers (1); letter to 
editor (1); study design description (1); full-text in Chinese 
(1). Figure 1 presents the study flow diagram with numbers 
of records screened, assessed for eligibility and included in 
the review. A total of six publications were included in this 
review: two reports of three RCTs: Stalmans et al,11 Dugel et 
al;12 and four reports that analyzed PRO outcomes from the 
same RCT: Gandorfer et al,23 Varma et al,29 Jackson et al,26 
Lescrauwaet et al.30
included studies
Six publications met the eligibility criteria. A brief summary 
of the study characteristics is provided below, and further 
details are provided in Table 1.
Participants
The three RCTs included 872 participants (872 eyes): 
Microplasmin for Intravitreous Injection – Traction Release 
without Surgical Treatment (MIVI-TRUST) 006, N=326; 
MIVI-TRUST 007, N=326 (clinicaltrials.gov identifier: 
NCT00781859 and NCT00798317, respectively); Ocriplas-
min for Treatment for Symptomatic Vitreomacular Adhesion 
Including Macular Hole (OASIS) trial, N=220 (clinicaltrials.
gov identifier: NCT01429441). The age range was 18–97 
years (Table 2). In the OASIS study, eyes with an epiretinal 
membrane (ERM) were excluded but otherwise the eligibility 
criteria were similar across studies.
interventions
MIVI-TRUST 006 and MIVI-TRUST 007 both compared 
a single injection of ocriplasmin 0.125 mg with a placebo 
(saline) injection, while the OASIS study compared ocriplas-
min 0.125 mg with a sham injection (syringe hub pressed 
into conjunctiva to simulate an injection) which was assumed 
to better reflect natural history by removing a possible 
mechanical or volume effect of the saline injection causing 
VMA resolution.12
Outcomes
In the two primary research papers by Stalmans et al11 and 
Dugel et al12 the emphasis of the reported data involved clini-
cal efficacy outcomes such as the primary endpoint of phar-
macologic VMA resolution at day 28, secondary endpoints 
including BCVA gain from baseline, nonsurgical macular hole 
closure, need for vitrectomy and safety outcomes with ocri-
plasmin as observed in the RCTs. Both primary study reports 
summarize results for the VFQ-25 composite score, however, 
at different time points (month 6 in MIVI-TRUST; month 24 
in OASIS). The report by Gandorfer et al focused on inves-
tigating the association between anatomical and functional 
outcomes, more specifically to describe how VMA resolution 
and macular hole closure in the MIVI-TRUST clinical trials 
impact visual function improvement (BCVA or VFQ-25).23
The report by Varma et al comprehensively described 
PRO data with ocriplasmin using the VFQ-25, more specifi-
cally change from baseline to month 6 for the composite and 
subscale scores and clinically meaningful change (≥5 points) 
in scores.29 In these four papers, the functional outcomes 
considered were unidimensional (either visual acuity or 
VFQ-25). In addition, all results were reported irrespective of 
vitrectomy, meaning if a patient’s eye disease deteriorated and 
required a vitrectomy this was not considered as a treatment 
failure (or nonresponse). The two reports by Jackson et al26 
and Lescrauwaet et al30 also reported secondary outcomes 
from the same RCTs, however, a patient-centered composite 
endpoint consisting of visual acuity, VFQ-25 and need for 
vitrectomy was reported. In these responder analyses, a 
patient was considered a visual function responder when a 
clinically meaningful improvement in any of these principal 
traits of visual functioning was achieved, without the need 
for a vitrectomy.
Data synthesis
The search identified six papers with comparative PRO data 
on ocriplasmin vs placebo or sham injection from three tri-
als. No trial reported data for the same PRO measure. Due 
to differences in PRO methodology, a random-effect model 
was used to synthesize the individual study results.
excluded studies
We excluded 31 papers after reviewing full-text copies (Table 
S2 for details.
Risk of bias in included studies
The authors’ judgements about each risk of bias item (ran-
dom sequence generation; allocation concealment; blinding 
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Table 1 Characteristics of studies included in the review (partially extracted from Neffendorf et al16)
PICOS Study characteristics
enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes Stalmans et al11
Participants inclusion criteria: aged >18 years; focal VMA (vitreous adhesion to macula within 6 mm central retinal field surrounded 
by elevation of posterior vitreous cortex, as seen on OCT) that in the opinion of investigator was related to decreased 
visual function (eg, metamorphopsia, decreased visual acuity or other visual complaint); BCvA ≤20/25 in study eye; BCvA 
≥20/800 in non-study eye.
exclusion criteria: any evidence of proliferative retinopathy or exudative AMD or retinal vein occlusion in study eye; 
people with any vitreous hemorrhage or any other vitreous opacification which precludes either: visualization of posterior 
pole by visual inspection OR adequate assessment of macula by either OCT or fluorescein angiogram (or both) in study 
eye; FTMH >400 µm in diameter in study eye; aphakia in study eye; high myopia (> –8 diopters); uncontrolled glaucoma; 
lenticular or zonular instability; history of retinal detachment in either eye; prior vitrectomy or prior laser photocoagulation 
of macula; treatment with ocular surgery, intravitreal injection or retinal laser photocoagulation in the previous 3 months.
Intervention and
Comparator
Single intravitreal injection of ocriplasmin 125 µg in 0.10 mL volume.
Single intravitreal injection of 0.10 mL placebo with identical drug vehicle diluted with saline.
Outcomes, 
including the
PRO measure 
Primary outcome, as defined in study reports: the primary endpoint was the proportion of eyes with nonsurgical 
resolution of vMA at day 28 post-injection, as determined by masked OCT evaluation obtained from the CRC
Secondary outcomes, as defined in study reports: proportion of eyes with total PVD at day 28, as determined by B-scan 
ultrasound; need for vitrectomy; closure of a FTMH; gain ≥3-lines BCvA without vitrectomy; change from baseline in 
BCvA and vFQ-25 score at 6 months.
Adverse events reported: yes
intervals at which outcomes assessed: 7, 14, 28, 90 and 180 days
Study design Randomized controlled trials: Mivi 6 and Mivi 7, with pooled analysis
Length of follow-up: 180 days
Years study conducted: 2008–2010
Results of the 2-year ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (oasis) randomized trial Dugel et al12
Participants inclusion criteria: aged >18 years; presence of symptomatic vMA/vMT; BCvA ≤20/32 in study eye; BCvA ≥20/800 in 
non-study eye
exclusion criteria: history or current evidence of PR, exudative AMD or retinal vein occlusion in the study eye; 
people with any vitreous hemorrhage or any other vitreous opacification which precludes either visualization of the 
posterior pole by visual inspection OR adequate assessment of the macula by OCT; MH >400 µm in diameter in the 
study eye; presence of epiretinal membrane; aphakia in study eye; high myopia (> –8 diopters in study eye); history of 
rhegmatogenous retinal detachment in either eye; prior vitrectomy in study eye; previous participation in this trial or 
prior administration of ocriplasmin in study eye.
Intervention and
Comparator
Single intravitreal injection of ocriplasmin 125 µg in 0.10 mL volume.
Sham (the same syringe hub was pressed against the conjunctiva to simulate an injection).
Outcomes, 
including the
PRO measure
Primary outcome, as defined in study reports: Proportion of subjects with pharmacological VMA/VMT resolution at day 
28. Pharmacological vMA resolution without anatomical defect, based on spectral domain optical coherence tomography 
and determined by the masked CRC, with post-resolution vitrectomy considered as a failure.
Secondary outcomes, as defined in study reports, were assessed at 24 months and irrespective of vitrectomy (where 
applicable): proportion of subjects with a ≥2-lines improvement in BCvA from baseline at month 24; proportion of 
FTMHs that closed without vitrectomy as determined by the CRC; proportion of subjects receiving a vitrectomy; 
proportion of subjects with a ≥3-line improvement in BCvA from baseline; mean change in BCvA from baseline; and 
proportion of subjects with a ≥5-point improvement in the vFQ-25 composite score from baseline.
Adverse events reported: yes
intervals at which outcomes assessed: 7 and 28 days; 3, 6, 9, 12, 15, 18, 21 and 24 months
Study design Randomized controlled trial
Length of follow-up; 24 months
Years of study conducted: 2011–2014
Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular 
adhesion/vitreomacular traction, including when associated with macular hole Gandorfer et al23
Participants Pooled Mivi 6 and Mivi 7 study population as reported by Stalmans et al.11
Intervention and
Comparator
Single intravitreal injection of ocriplasmin 125 µg in 0.10 mL volume.
Single intravitreal injection of 0.10 mL placebo with identical drug vehicle diluted with saline.
Outcomes, 
including the
PRO measure
BCvA: mean and categorical changes from baseline in BCvA (irrespective of vitrectomy).
vFQ-25: mean changes from baseline in the vFQ-25 scores.
Responder analyses by success or failure to achieve nonsurgical resolution of vMA at day 28 and nonsurgical FTMH 
closure at day 28.
(Continued)
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PICOS Study characteristics
Study design
and notes
Analyses from randomized controlled studies Mivi 6 and Mivi 7
An ANOvA model with factors for subgroup (success/failure on the anatomical endpoint), study, and baseline visual 
acuity category (<65, 65–75, >75 letters) was used to compare between responder subgroups. A similar model was used 
for vFQ-25 with a factor adjusting for baseline in the vFQ-25.
For categorical changes in BCVA, the Cochran–Mantel– Haenszel test, stratified by study, was used to make comparisons 
between responder subgroups.
improvement in patient-reported visual function after ocriplasmin for vitreomacular adhesion results of the microplasmin for intravitreous 
injection-traction release without surgical treatment (mivi-trust) trials varma et al29
Participants Pooled Mivi 6 and Mivi 7 study population as reported by Stalmans et al.11
Intervention and
Comparator
Single intravitreal injection of ocriplasmin 125 µg in 0.10 mL volume.
Single intravitreal injection of 0.10 mL placebo with identical drug vehicle diluted with saline.
Outcomes, 
including the
PRO measure
vFQ-25 composite and subscale scores
Mean changes between baseline and 6-month follow-up.
Proportion of patients with a clinically meaningful change (≥5 points) in scores.
Study design
and notes
Analyses from 2 randomized controlled clinical trials comparing change in patient-reported visual function.
Comparison ocriplasmin vs placebo: (1) mean changes from baseline in vFQ-25 scores*; (2) proportion of patients 
with ≥5-point improvement or worsening in vFQ-25 scores.**
Comparison ocriplasmin patients who met the primary endpoint vs those who did not: (1) mean changes from baseline in 
vFQ-25 scores;* (2) proportions of patients with ≥5-point improvement or worsening in vFQ-25 scores.**
visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole Jackson et al26
Participants Pooled Mivi 6 and Mivi 7 study population as reported by Stalmans et al.11
Intervention and
Comparator
Single intravitreal injection of ocriplasmin 125 µg in 0.10 mL volume.
Single intravitreal injection of 0.10 mL placebo with identical drug vehicle diluted with saline.
Outcomes, 
including the
PRO measure
The main outcome measure was visual function response at 6 months, defined as either a BCVA improvement of  ≥2 
lines; or an improvement in the composite score of the vFQ-25 exceeding the MCiD, estimated using the standard error 
of measurement approach; or an improvement in the vFQ-25 driving subscale score exceeding the MCiD.
Study design Post hoc analysis of prespecified secondary endpoints in two multicenter, randomized, double-masked, Phase III clinical 
trials
visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole: the oasis study Lescrauwaet et al30
Participants OASiS study population as reported by Dugel et al.12
Intervention and
Comparator
Single intravitreal injection of ocriplasmin 125 µg.
Sham
Outcomes, 
including the
PRO measure
The main outcome measure was the visual function response at month 6, with further assessments at months 12 and 24. 
VFR was defined as either a VA improvement of ≥2 lines or an improvement exceeding the MCiD in the composite or the 
mental health subscale scores of the vFQ-25. The MCiD was estimated using the standard error of measurement approach.
Study design Prespecified analysis of secondary endpoints from a randomized controlled trial (OASIS study).
Notes: *ANOvA model, with treatment, age, sex, race, baseline vFQ-25 score, and study as covariates. **Cochran–Mantel–Haenszel test, with stratification for age group, 
sex, race, and study. Reprinted with permission from Neffendorf Je, Kirthi v, Pringle e, Jackson TL. Ocriplasmin for symptomatic vitreomacular adhesion. Cochrane Database 
Syst Rev. 2017;10:CD011874, John wiley and Sons.16
Abbreviations:  BCvA, best corrected visual acuity; CRC, central reading center; FTMH, full-thickness macular hole; MH, macular hole; MCiD, minimal clinically important 
difference; OCT, optical coherence tomography; PR, proliferative retinopathy; PvD, posterior vitreous detachment; PiCOS, Participants interventions Comparators Outcomes 
Study design; vFQ-25, visual Function Questionnaire 25; vFR, visual function response; vMA, vitreomacular adhesion; vMT, vitreomacular traction; AMD, age-related macular 
degeneration.
Table 1 (Continued)
of participants and personnel; incomplete outcome data; 
selective reporting; other bias) for each RCT is summarized 
in Figure S1. Overall, the studies were judged to have a low 
risk of bias based on the diagram provided.
Results of individual studies
Demographic and ocular baseline characteristics were gen-
erally comparable between treatment groups. As reported 
previously, 22.8% vs 25.0% of MIVI-TRUST patients had a 
FTMH associated with VMT at baseline in the ocriplasmin vs 
placebo group, respectively.11,29 In OASIS, these proportions 
were slightly higher, but remained comparable between ocri-
plasmin (34.5%) vs sham (35.6%) groups.12 Mean baseline 
BCVA scores (ETDRS letters) were similar across studies 
and treatments: 63.9 vs 65.1 letters in the MIVI-TRUST 
ocriplasmin vs placebo groups, respectively,11,29 and 63.5 vs 
62.4 letters in the ocriplasmin vs sham OASIS groups, 
respectively.12 Mean baseline composite VFQ-25 scores were 
lower for ocriplasmin: 77.1 vs 82.0 in the MIVI-TRUST 
ocriplasmin vs placebo groups, respectively29 and 77.6 vs 
81.8 in the OASIS ocriplasmin vs sham groups (Mein, 2017, 
conference proceeding, unpublished data). Mean general 
vision subscale scores were 62.1 (ocriplasmin) and 65.5 
(placebo).29 Table 2 shows baseline characteristics across 
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the individual ocriplasmin studies (MIVI 006, MIVI 007, 
OASIS), and the combined studies.
Notwithstanding differences in anatomical disease char-
acteristics across the individual studies, baseline BCVA was 
quite comparable across studies, while functional vision 
(measured by the VFQ-25) showed more variability (Table 2).
Burden of visual dysfunction in vMT
Evaluating visual dysfunction brings important information to 
determine the need for treatment. The MIVI-TRUST and OASIS 
trials collected PRO outcomes (VFQ-25 data) prior to treatment 
with ocriplasmin or control, and give an insight into the impact 
of VMT. The baseline VFQ-25 subscale scores are summarized 
in Table 3. Table 3 also shows the scores for several chronic eye 
diseases, low vision and the healthy reference groups examined 
in the NEI VFQ Field Test, for comparison.24 Most VMT sub-
scale scores were lower than the healthy reference group, and 
with greater variability (represented by the SD), suggesting the 
impact of VMT varies substantially between individuals.
In the ocriplasmin studies, patients reported their visual 
disability at baseline as being the greatest for the general 
vision subscale, with a mean score of approximately 63.29 The 
next three most impacted vision-targeted domains in VMT 
patients were near activities (score =69), mental health (score 
=71) and role functioning (score =72) (Figure 2).
effect of treatment on patient reported 
outcomes
Compared with no treatment, ocriplasmin was found to 
increase the chance of traction resolution within 28 days.16 
What the treatment effect on a surrogate (anatomical) 
 endpoint signifies in terms of improved patient functioning 
is synthesized for two PROs, namely the VFQ-25 composite 
score and the visual function response measures.
visual Function Questionnaire-25 items
In MIVI-TRUST, short-term (month 6), improvements from 
baseline in the VFQ-25 composite score and each subscale 
score were numerically better in the ocriplasmin vs the pla-
cebo group, with a notable improvement in the general vision 
subscale score in favor of ocriplasmin (6.1, ocriplasmin vs 
2.1, placebo). Improvements in the composite score were 3.4 
(ocriplasmin) vs 0.7 (placebo).11,23,29
Assuming a ≥5-point improvement as clinically mean-
ingful, a greater proportion of ocriplasmin-treated patients 
(36.0%) had meaningful increase in the NEI VFQ-25 com-
posite score vs placebo (27.2%).29 In OASIS, this treatment 
difference (21.3%) was maintained in the long-term (month 
24) in favor of ocriplasmin (51.4%) vs sham (30.1%).12 
Results were reported regardless of whether the patient 
underwent a vitrectomy or not, and the analysis applied last 
observation carried forward for missing values.
Combining the total of 870 participants from the individual 
studies, the pooled results for the VFQ-25 composite score 
responder analysis shows a higher proportion of patients (11.8%) 
experience a clinically meaningful improvement in visual func-
tioning with ocriplasmin compared to control (Table 4).
visual function response – a composite endpoint
From the ocriplasmin clinical studies, a composite functional 
endpoint called visual function response (VFR) was devel-
oped.26 This endpoint was composed of three scores (clinical 
Table 2 Baseline characteristics of patients with vMT in investigational studies
 MIVI 006
(N=326)
MIVI 007
(N=326)
OASISa
(N=218)
Combined
(N=870)
Demographics     
Female N (%) 207 (63.5) 222 (68.1) 147 (67.4) 576 (66.2)
white race N (%) 292 (89.6) 310 (95.1) 195 (89.4) 797 (91.6)
Age, years: mean (SD) 71.3 (10.2) 72.0 (8.5) 69.1 (10.3) 71 (9.7)
Anatomical characteristics
FTMH present N (%) 89 (27.3) 64 (19.6) 76 (34.9) 229 (26.3)
eRM present N (%) 121 (37.7) 131 (40.9) 50 (22.9) 302 (35.2)
Ocular characteristics
BCvA, mean (SD)b 64.8 (10.5) 63.8 (13.2) 63.0 (9.8) 64.0 (11.5)
VFQ-25 composite scorec,d
vFQ-CS, mean (SD) 80.2 (14.1) 76.8 (15.8) 78.9 (14.4) 78.6 (14.9)
Notes: aA total of 220 participants received trial treatment, however one subject in each treatment group did not attend a post-injection visit and both were therefore 
not included in the full analysis population. bBaseline BCvA measurements were not available for 1 Mivi 006 and 1 OASiS participant. cComposite score is calculated as the 
mean of the 11 vision-targeted subscale scores, excluding the general health question.25 dBaseline vFQ-CS data were not available for 1 Mivi 006 and 2 Mivi 007 participants.
Abbreviations: eRM, epiretinal membrane; FTMH, full-thickness macular hole; vFQ-25, visual function questionnaire, 25-item form24; BCvA, best-corrected visual acuity; 
vMT, vitreomacular traction; Mivi, Microplasmin for intravitreous injection; OASiS, Ocriplasmin for Treatment for Symptomatic vitreomacular Adhesion including Macular 
Hole.
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proxies) namely the VFQ-25 composite score (CS), VFQ-25 
driving subscale and best corrected visual acuity (BCVA) 
in the case of the MIVI-TRUST analysis vs VFQ-CS, VFQ-
mental health score (MHS) and BCVA in the case of the 
OASIS analysis. Overall VFR was defined as an improvement 
exceeding the threshold of minimally clinically important dif-
ference (MCID) in any of the three principal traits of visual 
functioning identified from the PCA.26,30 Figure 3 summarizes 
the VFR responder results from both analyses. Overall VFR 
was quite consistent; half or more of ocriplasmin-treated 
subjects were considered an “overall VFR responder” (MIVI-
TRUST: 55.1%; 51.0% in OASIS), while this was the case 
for only 1 in 3 of MIVI-TRUST placebo patients (34.2%) and 
1 in 4 of OASIS sham patients (23.3%). In these responder 
Table 3 VFQ-25 subscale scores in selected vision conditions from the NEI VFQ field test sample (n=597) and in vMT studies
Diabetic 
retinopathy
AMD Glaucoma Cataract CMV 
retinitis
Low vision Healthy 
reference 
group
VMT
- MIVI, 
OASIS
(N=123) (N=108) (N=77) (N=93) (N=37) (N=90) (N=122) (N=870)
Subscales (mean ± SD)
General health 46±25 65±25a,b 62±25a,b 55±25 45±24 57±27 69±24 61±24
General vision 62±21 53±20 71±17 60±17 76±14b 38±18 83±15 63±16
Near vision 63±30 54±27 79±23 73±21 84±20b 36±23 92±13 69±21
Distance vision 66±30 56±29 77±25 73±22 84±18 38±26 93±11 75±20
Driving 55±40 39±36 75±28 63±30 80±28a,b 10±23 87±18 76±24
Peripheral vision 78±29 77±27 76±27 87±21 78±21 59±32 97±10 83±22
Color vision 90±22 85±25 93±17 90±20 98±9a,b 71±31 98±8 94±14
Ocular pain 88±17a,b 87±16a 89±14a,b 86±19b 90±16a,b 85±20a,b 90±15 84±19
Vision specific (mean ± SD)
Role difficulties 69±31 61±31 84±23 76±22 78±24 44±29 93±13 72±26
Dependency 77±30 72±30 92±19 88±20 89±12 51±31 99±5 88±20
Social functioning 81±26 73±29 89±20 87±19 96±9 50±31 99±3 91±16
Mental health 66±29 58±27 81±20 77±22 74±22 46±27 92±12 71±23
Composite score 72±22 65±21 82±17 78±14 84±11 49±19 93±7 79±15
Notes: Composite score data provided by Mangione and colleagues. aUnadjusted t-test comparison with healthy reference group participants was nonsignificant (P<0.05). 
bLinear regression result for 2-group comparison with the health reference group, adjusted for age, sex, race, and medical comorbidities, was nonsignificant (P<0.05). cData 
are presented as mean ± SD. All pairwise comparisons between each disease group and the healthy reference group were statistically significant at P<0.05, unless otherwise 
specified.
Abbreviations: CMv, cytomegalovirus; AMD, age-related macular degeneration; vFQ-25, visual Function Questionnaire 25; vMT, vitreomacular traction; Mivi, Microplasmin 
for intravitreous injection; OASiS, Ocriplasmin for Treatment for Symptomatic vitreomacular Adhesion including Macular Hole.
Table 4 Responder analysis for vFQ-25 composite score across studies (month 6 data) – irrespective of vitrectomy
Response criteria: composite scorea Ocriplasmin % (n/N) Control % (n/N) Difference (%) (95% CI)b P-valuec
Change from baseline ≥5 points
Mivi-TRUST 36.0 (154/428) 27.2 (47/173) 8.8 (0.8, 16.9) 0.045
OASiSd 39.3 (57/145) 21.9 (16/73) 17.4 (5.0, 29.8) 0.010
Combined 36.8 25.4 11.8 (3.8, 19.7) 0.004
Notes: aThe composite score is calculated as the mean of the 11 vision-targeted subscale scores, excluding the general health question. bDifference and Ci between 
treatment groups are based on the percentage of responses. cFor individual studies, the P-value is from Fisher’s exact test, comparing control and ocriplasmin. For combined 
studies, pooling of risk differences was based on random effects model using the method of DerSimonian and Laird.28 dEstimate based on non-stratified treatment effect, not 
weighted by FTMH strata.
Abbreviations: N, number of subjects in the dataset; n, number of subjects with a success for the endpoint; FTMH, full thickness macular hole; Mivi-TRUST, Microplasmin 
for intravitreous injection -Traction Release without Surgical Treatment; vFQ-25, visual Function Questionnaire 25; OASiS, Ocriplasmin for Treatment for Symptomatic 
vitreomacular Adhesion including Macular Hole.
analyses, a patient who required a vitrectomy surgery prior 
to the VFQ-25 assessment was automatically classified as a 
visual function nonresponder.
Combining the data from the individual studies, the 
pooled VFR results show 54.0% of ocriplasmin-treated 
patients experience a clinically meaningful improvement in 
visual functioning compared with 30.1% in the control group, 
representing a 23.2% difference (Table 5).
Association between PROs and 
anatomical outcomes
Release of vitreomacular traction was the primary endpoint in 
all RCTs of ocriplasmin which was measured as an imaging 
outcome by optical coherence tomography (OCT).11,12 These 
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surrogate (anatomical) outcomes are not of direct practical 
importance to patients, but are taken as being predictive of 
clinical outcomes (such as VA and QoL) of most importance 
to patients.31
Nonsurgical resolution of traction at day 28 was associ-
ated with functional outcomes: a 5-point improvement from 
baseline to month 6 was observed in the VFQ-25 composite 
score in patients (both treatment groups combined) who 
experienced a release of traction vs a 2-point improvement 
in those with persisting traction (P=0.003).23
Within treatment groups, ocriplasmin-treated patients 
with successful release also had a significantly higher 
improvement on the composite score compared to those 
with persisting traction (7.7 vs 2.6, P=0.003). However, this 
association was not observed in the placebo-treated patients 
(−0.2 vs 0.7, P=0.66).29
Significant associations were also found between a clini-
cally meaningful functional response for the VFQ-CS, BCVA 
Figure 2 vFQ-25 composite and subscale scores for vMT patients (investigational and healthy reference groups).
Notes: All pairwise combinations between VMT patients from investigational studies (MIVI, OASIS) vs the healthy reference groups were statistically significant at P<0.05. 
Composite score for healthy reference group calculated as mean of 11 subscale scores, excluding general health item (courtesy of Mangione and colleagues).
Abbreviations: vFQ-25, visual Function Questionnaire 25; vMT, vitreomacular traction; Mivi-TRUST, Microplasmin for intravitreous injection – Traction Release without 
Surgical Treatment; OASiS, Ocriplasmin for Treatment for Symptomatic vitreomacular Adhesion including Macular Hole.
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and overall VFR measures in patients who achieved release 
vs those with persisting adhesion (Figure 4).26,30
When pooling these results across the individual stud-
ies, we observed a higher proportion of patients with visual 
function response (60.6%) when release of traction occurred 
at day 28 compared with 42.3% of patients with persisting 
traction (Table 6).
Partial resolution of traction and 
treatment effect on PROs
In all RCTs of ocriplasmin, successful VMA resolution 
was strictly defined as a progression from a state where 
the vitreous was attached in or at the macula to a state in 
which VMA at the macula was absent. In the subgroup of 
patients with release of traction, no significant differences 
in response were observed between ocriplasmin and control 
for the composite outcome VFR or the VFQ-25 composite 
score. In the subgroup with persisting adhesion/traction, a 
 
Pa
tie
nt
 R
el
at
ed
 O
ut
co
m
e 
M
ea
su
re
s 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
61
.2
03
.1
44
 o
n 
25
-A
pr
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Related Outcome Measures 2019:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
111
Lescrauwaet et al
significantly higher proportion of functional responders was 
observed in the ocriplasmin-treated patients compared with 
the control group, for the overall VFR and VFQ-CS outcomes 
(Figure 5).26,30
When pooling these results across the individual studies, 
we observed that in the subgroup with persisting traction at 
Table 5 Responder analysis for vFR across studies (month six data)
Response criteria Ocriplasmin
% (n/N)
Control
% (n/N)
Difference (%)
(95%CI)b
P-valuec
visual Function Responsea
Mivi-TRUST 55.1 (217/394) 34.2 (53/155) 20.9 (11.9, 29.8) <0.001
OASiSd 51.0 (74/145) 23.3 (17/73) 27.7 (15.1, 40.4) <0.001
Combined 54.0 30.1 23.2 (15.9, 30.5) <0.001
Notes: aResponse criteria based on overall vFR composed of 3 dimensions determined by the PCA output (in Mivi-TRUST: vFQ-CS, vFQ-driving, BCvA; in OASiS vFQ-
CS, vFQ-MH, BCvA. bDifference and Ci between treatment groups are based on the percentage of responses. cFor individual studies, the P-value is from Fisher’s exact test, 
comparing control and ocriplasmin. For combined studies, pooling of risk differences was based on random effects model using the method of DerSimonian and Laird.28 
dEstimate based on non-stratified treatment effect, not weighted by FTMH strata.
Abbreviations: N, number of subjects in the dataset; n, number of subjects with a success for the endpoint; vFR, visual function response; PCA, principal component analysis; 
vFQ-CS, visual Function Questionnaire 25-composite score; vFQ-Driving, visual Function Questionnaire 25-driving subscale; vFQ-MHS, visual Function Questionnaire 
25-mental health subscale; FTMH, full thickness macular hole; BCvA, best corrected visual acuity; Mivi-TRUST, Microplasmin for intravitreous injection – Traction Release 
without Surgical Treatment; OASiS, Ocriplasmin for Treatment for Symptomatic vitreomacular Adhesion including Macular Hole.
Figure 3 Responder rates for visual function response variables by treatment (month 6). (A) Mivi. (B) OASiS.
Abbreviations: BCvA, best corrected visual acuity; vFR, visual function response; vFQ-CS, visual Function Questionnaire 25-composite score; vFQ-Driving, visual 
Function Questionnaire 25-driving; vFQ-MHS, visual Function Questionnaire 25-mental health subscale; Mivi-TRUST, Microplasmin for intravitreous injection – Traction 
Release without Surgical Treatment; OASiS, Ocriplasmin for Treatment for Symptomatic vitreomacular Adhesion including Macular Hole.
VFQ-CS
0
10
20
30
40
R
es
po
nd
er
s,
 %
50
60
A B
P=0.0016
35.9
23.7
33.8
55.1
28.3 29.2
51.0
10.2
22
.7
6.
2
11
.2
34
.2
12
.3
12
.3
16
.4
23
.3
P=0.1697 P=0.0003 P<0.0001
Ocriplasmin Control
P=0.0012 P=0.0101 P=0.0431 P=0.0001
VFQ-
driving
BVCA Overall
VFR
VFQ-CS VFQ-MHS BVCA Overall
VFR
day 28, a higher proportion of ocriplasmin-treated patients 
experience a visual function response (49.8%) compared to 
control (29.1%, P<0.001) (Table 7). This finding indicates 
that in the subgroup without complete release of adhesion/
traction, ocriplasmin confers visual functioning benefits to 
patients.
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Discussion
This review combined PROs from clinical trials of ocriplas-
min, given to treat VMT with or without a FTMH. We found 
that ocriplasmin produces significant patient benefit vs con-
trol (sham or placebo-injection) treatment. Ocriplasmin was 
associated with a higher proportion of patients experiencing 
a clinically meaningful improvement in visual functioning 
(11.8% for VFQ-25 composite score analysis; 23.2% for VFR 
responder analysis). The studies were of high quality, being 
Table 6 vFR responder analysis by vMA outcome across studies (month six data)
Response criteria VMA release
% (n/N)
Persisting VMA
% (n/N)
Difference (%)
(95% CI)b
P-valuec
visual Function Responsea
Mivi-TRUST 62.5 (80/128) 45.1 (190/421) 17.4 (7.7, 27.0) 0.001
OASiSd 56.7 (38/67) 35.1 (53/151) 21.6 (7.5, 35.7) 0.004
Combined 60.6 42.3 18.7 (10.8, 26.7) <0.001
Notes: aResponse criteria based on overall vFR composed of three dimensions determined by the PCA output (in Mivi-TRUST: vFQ-CS, vFQ-driving, BCvA; in OASiS 
vFQ-CS, vFQ-MH, BCvA. bDifference and Ci between treatment groups are based on the percentage of responses. cFor individual studies, the P-value is from Fisher’s exact 
test, comparing vMA release and persisting vMA. For combined studies, pooling of risk differences was based on random effects model using the method of DerSimonian 
and Laird.28 dEstimate based non-stratified treatment effect, not weighted by FTMH strata.
Abbreviations: N, number of subjects in the dataset. n, number of subjects with a success for the endpoint; vFR, visual function response; PCA, principal component analysis; 
vFQ-CS, visual Function Questionnaire 25-composite score; vFQ-driving, visual Function Questionnaire 25-driving subscale; vFQ-MHS, visual Function Questionnaire 
25-mental health subscale; FTMH, full thickness macular hole; Mivi-TRUST, Microplasmin for intravitreous injection – Traction Release without Surgical Treatment; OASiS, 
Ocriplasmin for Treatment for Symptomatic vitreomacular Adhesion including Macular Hole.
Figure 4 Responder rates for visual function response measures by anatomical outcome (Month 6). (A) Mivi. (B) OASiS.
Abbreviations: BCvA, best corrected visual acuity; vMA, vitreomacular adhesion; vFR, visual function response; vFQ-CS, visual Function Questionnaire 25-composite 
score; vFQ-Driving, visual Function Questionnaire 25-driving subscale; vFQ-MHS, visual Function Questionnaire 25-mental health subscale.
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randomized, double-masked, and sham or placebo controlled, 
with a consequent low risk of bias. Only studies with NEI 
VFQ-25 were found. A definition of VFR was derived using 
a principal component analysis which combined VFQ-25 and 
BCVA.26,30 There was no evidence of significant heterogeneity 
for the pooled PRO outcomes (I2 <50%). However, there were 
differences in methodological approaches to outcome defini-
tions or in methods for dealing with intercurrent vitrectomy; 
hence we judged the risk of other bias as unclear.
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PRO measures provide an opportunity to measure out-
comes that resonate with patients, and reveal the patient’s 
perspective on the impact of disease and the value of treat-
ments. Yet, the reality is that the evidence is limited and 
dominated by VFQ-25 data from the investigational studies. 
Ongoing observational studies will likely enrich the amount 
of PRO evidence.
The NEI VFQ-25 is a widely used validated questionnaire 
used for a range of eye diseases.32,33 It is likely to capture 
patient symptomatology better than a generic measure of 
health-related QoL tool, such as EuroQol EQ-5D, which 
instead aims to estimate preferences for a particular health 
state (health utilities).34,35However, the VFQ-25 is not specifi-
cally developed for retinal diseases, and given the symptoms 
Table 7 vFR response at month 6, by vMA status at day 28
 Ocriplasmin
% (n/N)
Control
% (n/N)
Difference (%)
(95%CI)b
P-valuec
vMA release at day 28
Mivi-TRUST 64.3 (72/112) 50.0 (8/16) 14.3 (–11.8, 40.3) 0.283
OASiSd 59.7 (37/62) 20.0 (1/5) 39.7 (2.6, 76.8) 0.158
Combined 62.7 40.2 23.5 (–8.0, 47.8) 0.058
Persisting vMA at day 28
Mivi-TRUST 51.4 (145/282) 32.4 (45/139) 19.0 (9.3, 28.8) <0.001
OASiSd 44.6 (37/83) 23.5 (16/68) 21.0 (6.4, 35.7) 0.010
Combined 49.8 29.1 19.7 (11.5–27.8) <0.001
Notes: aResponse criteria based on overall vFR composed of three dimensions determined by the PCA output (in Mivi-TRUST: vFQ-CS, vFQ-driving, BCvA; in OASiS 
vFQ-CS, vFQ-MH, BCvA. bDifference and Ci between treatment groups are based on the percentage of responses. cFor individual studies, the P-value is from Fisher’s exact 
test, comparing control and ocriplasmin. For combined studies, pooling of risk differences was based on random effects model using the method of DerSimonian and Laird.28 
dEstimate based non-stratified treatment effect, not weighted by FTMH strata.
Abbreviations: N, number of subjects in the dataset; n, number of subjects with a success for the endpoint; vFR, visual function response; vMA; vitreomacular adhesion; 
PCA, principal component analysis; vFQ-CS, visual Function Questionnaire 25-composite score; vFQ-driving, visual Function Questionnaire 25-driving subscale; vFQ-MHS, 
visual Function Questionnaire 25-mental health subscale; FTMH, full thickness macular hole; Mivi-TRUST, Microplasmin for intravitreous injection – Traction Release 
without Surgical Treatment; OASiS, Ocriplasmin for Treatment for Symptomatic vitreomacular Adhesion including Macular Hole; BCvA, best corrected visual acuity.
Figure 5 visual function outcomes by vMA subgroups. (A) Overall visual function response. (B) visual function composite score.
Abbreviations: vMA, vitreomacular adhesion; vFQ-25, visual Function Questionnaire 25.
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of VMT it would be preferable to also have a validated 
disease-specific questionnaire.20 To examine the influence 
of VMT on patient functioning, recommendations for future 
research include the development of new PROs in VMT. 
This process can be initiated with focus group discussions 
to appreciate the outcomes that matter to patients with VMT, 
explore the principal traits of functional vision through a PCA 
of the VFQ-25 items from all studies, test the psychometric 
properties of the VFQ-25 through Rasch analysis using both 
the VFQ-25 and metamorphopsia questionnaires, estimate 
VFQ-UI utility values, including its psychometric properties.
In the primary ocriplasmin publications, the reported effi-
cacy data focused on anatomical and BCVA outcomes, which 
is understandable as these are clinically accepted outcome 
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measures. Further, release of VMA and nonsurgical closure 
of macular hole were each associated with improved visual 
functioning in patients with VMT, as evidenced by favorable 
outcomes in BCVA and VFQ-25.23,29
It is worth noting that patients enrolled in the ocriplas-
min investigational studies, compared with observational 
nondrug studies like the MeMo Study, reported higher QoL 
impairment in all VFQ-25 subscales except ocular pain (Table 
S3).13 In addition, the variability in almost all vision-targeted 
subscales was larger than in a healthy reference group, sug-
gesting that VMT patients may be more affected in a certain 
vision domain than others. More specifically, general vision 
and near distance activities were most impacted, which could 
be expected as it is consistent with the underlying diagnosis 
of VMT where not only reduced central visual acuity but 
also other symptoms such as metamorphopsia or micropsia 
contribute to morbidity. However, the impact on mental health 
and role functioning deserves further investigation.36–38These 
findings underpin the importance to test the psychometric 
properties of the VFQ-25 in patients with VMT.
Different approaches were taken in the analysis of the 
PRO endpoints. The visual function responder analysis uses 
a composite functional endpoint, instead of single VFQ-25 
data, and values clinically meaningful improvements the 
patient experiences in any of the events specified by the com-
ponents. A composite endpoint has the advantage that it can 
combine patient-, observer- or clinician-reported measures or 
that it avoids an arbitrary choice between several important 
outcomes associated with a patient’s disease status (visual 
acuity, daily functioning, mental health, etc).39
Other differences included the analysis approach to vit-
rectomy. A vitrectomy after initial treatment represents an 
additional burden to the patient due to the recovery period 
or long-term risks (cataract development). The occurrence 
of vitrectomy was assumed a rescue therapy; hence patients 
requiring a vitrectomy were considered a visual function 
failure. Thus, the visual function responder analysis integrates 
patient burden in its PRO construct. The VFQ-25 responder 
results instead, were analyzed irrespective of vitrectomy out-
comes, an approach that impacts the pooled risk difference 
from 11.8% (Table 4) to 15.2% (Table S4).
Finally, this review alludes to the caveats with the use of 
surrogate vs patient-reported endpoints in drug development. 
In patients who achieved anatomical success, no significant 
differences in response were observed between ocriplasmin 
and control for the composite VFR outcome (or VFQ-25 
measure), which underlines the relevance of the surrogate 
endpoint. The analyses by Gandorfer et al and Varma et al 
also confirmed the importance of achieving an anatomical 
endpoint (release of traction) on unidimensional functional 
outcomes (VFQ-25 or BCVA).23,29
However, along the same lines a treatment effect was 
observed in patients who did not experience an anatomi-
cal success. This suggests that patients treated with ocri-
plasmin vs control might still benefit from partial release 
of traction, so the surrogate endpoint defined as a binary 
response was unable to capture the functional improvement 
after treatment. The area of traction is important for thera-
peutic recommendation; hence the need for a more precise 
description of the area of traction in eyes with VMT.40 The 
patient’s perspective does matter in the quantification of 
functional benefit.
This review of PROs with ocriplasmin in the treatment of 
vitreomacular traction followed a protocol which included a 
comprehensive search strategy using a published search filter, 
which was expanded by additional terms for disease-specific 
QoL instruments. Nevertheless, our search resulted in a 
limited set of publications reporting on PROs. Linking the 
patient’s perspective to NEI VFQ-25 evidence has limitations 
as it is a broad measure of visual functioning and does not 
specifically assess some of the visual symptoms commonly 
experienced by patients with VMT such as the distortion, 
or micropsia.9,28 The VFQ-25 was designed to measure a 
patients’ subjective assessments of visual function, and was 
validated for persons with vision problems, but not designed 
for one specific (retinal) vision condition.9,24 It has been criti-
cized for floor and ceiling effects, for not being appropriate 
in certain ophthalmic indications, and for not having been 
validated in patients with VMT.9,23,24,41,42
When combining the PRO results, we used data from 
available reports on visual function response. This composite 
measure comprehensively evaluated changes in vision-related 
functioning. Applying a PCA, a well-established data reduction 
technique, the most relevant principal components correlated 
best with the VFQ-25 composite score in both the MIVI-
TRUST and OASIS datasets. Conversely, the VFQ-25 driving 
subscale correlated best with the second principal components 
in the MIVI dataset, while the VFQ-25 mental health subscale 
correlated best with the second and third principal components 
in the OASIS dataset. In both datasets, BCVA correlated poorly 
with either principal components and was therefore considered 
to add independent information. Due to the use of different 
definitions in the PRO, heterogeneity (between-study varia-
tion in effect) may have been introduced, which can limit the 
validity of the pooled treatment effect estimate. However, a 
sensitivity analysis, in which the visual function response was 
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based on the two common scores (VFQ-25 composite score 
and BCVA) generated similar results (Tables S5–S7).
Conclusion
This review recorded the impairment in visual function-
ing and vision-related quality of life in patients with VMT. 
Despite the relatively preserved visual acuity in these 
patients, the functional burden appears substantial.
The need for a brief multidimensional vision-targeted 
PRO measure is illustrated by the widespread use of the VFQ-
25, nonetheless uncertainty about its sensitivity to visual 
disability associated with milder forms of VMT remains.
In the absence of an anatomical tool for evaluation of 
this specific patient population, the randomized studies had 
included the VFQ-25 as the best available PRO instrument. 
To examine the influence that VMT disease and interventions 
have on a patient’s day-to-day functioning, recommendations 
for future research include the development of new PROs 
in VMT.
Finally, the observation that patients benefit functionally 
from treatment with ocriplasmin despite absence of resolu-
tion of the underlying anatomical condition merits further 
investigation to assess which endpoints in future trials may 
help more accurately quantify and compare the functional 
benefits of different treatment options.
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